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Key Points
• Severe malaria mainly affects children under 5 years old, non-immune travellers, migrants to malarial areas, and
people living in areas with unstable or seasonal malaria.
Cerebral malaria, causing encephalopathy and coma, is fatal in around 20% of children and adults, and neuro-
logical sequelae may occur in some survivors.
Severe malarial anaemia may have a mortality rate of over 13%.
• International consensus has historically regarded quinine  as standard treatment for severe falciparum malaria.
Controlled trials will generally compare new treatments against this standard.
We found no clear evidence on the best quinine treatment regimen or route of administration to use, although
high initial dose quinine clears parasites more rapidly compared with lower-dose quinine, but increases the risk
of adverse effects.
Intravenous artesunate  is probably more effective than quinine in reducing mortality from severe malaria.
Intramuscular artemether  and rectal artemisinin, artemether, artesunate, and dihydroartemisinin  may be as
effective as quinine in reducing mortality from severe malaria.
We don't know how intramuscular arteether  compares with quinine.
Routine use of phenobarbitone  in cerebral malaria may reduce convulsions compared with placebo, but can
increase mortality.
Dexamethasone  has not been shown to reduce mortality from severe malaria, and it increases the risk of gas-
trointestinal bleeding and seizures.
• We don't know whether initial blood transfusion  or exchange blood transfusion  reduce mortality from severe
malaria as no adequate-quality studies have been found. Blood transfusion is associated with adverse effects, but
is clinically essential in some circumstances.
Infectious diseases
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DEFINITION Falciparum malaria is caused by protozoan infection of red blood cells with Plasmodium falciparum
and comprises a variety of syndromes. This review deals with clinically complicated malaria (i.e.
malaria that presents with life-threatening conditions, including coma, severe anaemia, renal failure,
respiratory distress syndrome, hypoglycaemia, shock, spontaneous haemorrhage, and convulsions).
The diagnosis of cerebral malaria should be considered where there is encephalopathy in the
presence of malaria parasites. A strict definition of cerebral malaria requires the presence of un-
rousable coma and no other cause of encephalopathy (e.g. hypoglycaemia, sedative drugs), in the
presence of P falciparum infection. [1] This review does not currently cover the treatment of
malaria in pregnancy.
INCIDENCE/
PREVALENCE
Malaria is a major health problem in the tropics, with 300–500 million clinical cases occurring an-
nually and an estimated 1.1–2.7 million deaths each year as a result of severe malaria. [2]  Over
90% of deaths occur in children under 5 years old, mainly from cerebral malaria and anaemia. [2]
In areas where the rate of malaria transmission is stable (endemic), those most at risk of acquiring
severe malaria are children under 5 years old, because adults and older children have partial im-
munity, which offers some protection. In areas where the rate of malaria transmission is unstable
(non-endemic), severe malaria affects both adults and children. Non-immune travellers and migrants
are also at risk of developing severe malaria.
AETIOLOGY/
RISK FACTORS
Malaria is transmitted by the bite of infected female anopheline mosquitoes. Certain haemoglobins
such as haemoglobin S [3]  and haemoglobin C [4]  are protective against severe malaria (see aeti-
ology in review on malaria: prevention in travellers). [5]
PROGNOSIS In children under 5 years of age with cerebral malaria, the estimated case fatality of treated
malaria is 19%, although reported hospital case fatality may be as high as 40%. [1] [6]  Neurological
sequelae persisting for more than 6 months may occur in some survivors, and include ataxia,
hemiplegia, speech disorders, behavioural disorders, epilepsy, and blindness. Severe malarial
anaemia may have a case fatality rate higher than 13%. [6]  In adults, the mortality of cerebral
malaria is 20%; this rises to 50% in pregnancy. [7]
AIMS OF
INTERVENTION
To prevent death and cure the infection; to prevent long term disability; to minimise neurological
sequelae resulting from cerebral malaria, with minimal adverse effects of treatment.
OUTCOMES Death; parasite clearance; parasite clearance time ; fever clearance time ; time to walking and
drinking; coma recovery time ; neurological sequelae at follow up; adverse events.
METHODS BMJ Clinical Evidence search and appraisal December 2006. We applied the World Health Orga-
nization criteria for severe malaria when deciding which RCTs to include. [1]  International consensus
has historically recommended quinine for the treatment of severe falciparum malaria. Placebo or
no treatment controlled trials of antimalarial treatment in people with severe malaria would be
considered unethical. The following databases were used to identify studies for this systematic
review: Medline 1966 to December 2006, Embase 1980 to December 2006, and The Cochrane
Database of Systematic Reviews and Cochrane Central Register of Controlled Clinical Trials 2006,
Issue 4. Additional searches were carried out using these websites: NHS Centre for Reviews and
Dissemination (CRD) — for Database of Abstracts of Reviews of Effects (DARE) and Health
Technology Assessment (HTA), Turning Research into Practice (TRIP), and National Institute for
Health and Clinical Excellence (NICE). Abstracts of the studies retrieved from the initial search
were assessed by an information specialist. Selected studies were then sent to the author for ad-
ditional assessment, using predetermined criteria to identify relevant studies. Study design criteria
for evaluation in this review were: published systematic reviews and RCTs in any language, and
containing more than 20 individuals of whom more than 80% were followed up. The minimum
length of follow-up required to include studies was 28 days. In addition, we use a regular surveillance
protocol to capture harms alerts from organisations such as the US Food and Drug Administration
(FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA), which are
added to the reviews as required.We have performed a GRADE evaluation of the quality of evidence
for interventions included in this review ( see table, p 14 ).
QUESTION What are the effects of antimalarial treatments for complicated falciparum malaria in non-
pregnant people?
OPTION INTRAMUSCULAR ARTEMETHER VERSUS QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
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Compared with quinine Intramuscular artemether seems to be as effective as quinine at reducing mortality in people
with severe malaria ( moderate-quality evidence ).
Fever clearance
Compared with quinine Intramuscular artemether seems to be as effective as quinine at eradicating fever in people
with severe malaria (moderate-quality evidence).
Recovery from coma
Compared with quinine Intramuscular artemether seems to be as effective as quinine at reducing time spent in a
coma in people with severe malaria (moderate-quality evidence).
Neurological sequelae
Compared with quinine Intramuscular artemether seems to be as effective as quinine at preventing neurological
sequelae in people with severe malaria ( high-quality evidence ).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found two systematic reviews [8] [9]  and five subsequent RCTs. [10] [11] [12] [13] [14] The first
review (search date not reported, 7 RCTs, 1919 adults and children) analysed individual participant
data. [8]  It found no significant difference in mortality between intramuscular artemether and either
intravenous or intramuscular quinine (im quinine in 1 RCT only) in severe falciparum malaria
(mortality: 136/961 [14%] with artemether v 164/958 [17%] with quinine; OR 0.80, 95% CI 0.62 to
1.02). Parasite clearance was faster with artemether than with quinine (HR 0.62, 95% CI 0.56 to
0.69). The review found no significant difference in the speed of coma recovery, fever clearance
time , or neurological sequelae between artemether and quinine ( coma recovery time  with quinine:
HR 1.09, 95% CI 0.97 to 1.22; fever clearance time with quinine: HR 1.01, 95% CI 0.90 to 1.15;
neurological sequelae: 81/807 [10%] with artemether v 91/765 [12%] with quinine; OR 0.82, 95%
CI 0.59 to 1.15). It found that rates for the combined outcome of death or neurological sequelae
were significantly lower for artemether than for quinine (OR 0.77, 95% CI 0.62 to 0.96; P = 0.02).
The second review (search date 1999, 11 RCTs, 2142 people) found a small significant reduction
in mortality for intramuscular artemether compared with intravenous quinine (OR 0.72, 95% CI
0.57 to 0.91). [9]  However, more rigorous analysis, excluding three poorer quality RCTs, found no
significant difference in mortality (OR 0.79, 95% CI 0.59 to 1.05). The review found no significant
difference in neurological sequelae at recovery between artemether and quinine (OR 0.8, 95% CI
0.52 to 1.25). The first subsequent RCT (105 people, aged 15–40 years, with cerebral malaria in
Bangladesh) compared intramuscular artemether (160 mg initially, then 80 mg/kg once daily) versus
intravenous quinine (loading dose 20 mg/kg, then 10 mg/kg 8-hourly). [10]  It found no significant
difference in death rates or neurological sequelae between artemether and quinine (death: 9/51
[18%] with artemether v 10/54 [19%] with quinine, OR 0.94, 95% CI 0.35 to 2.55; neurological se-
quelae: 3/51 [6%] with artemether v 1/54 [2%] with quinine, RR 3.18, 95% CI 0.34 to 29.56). Mean
fever clearance time and coma recovery time were significantly longer for artemether than for quinine
(fever clearance time: 58 hours with artemether v 47 hours with quinine, WMD 11.0 hours, 95%
CI 1.6 hours to 20.4 hours; coma recovery time: 74 hours with artemether v 53 hours with quinine,
WMD 20.8 hours, 95% CI 3.6 hours to 38.0 hours). There was no significant difference in mean
parasite clearance time  between artemether and quinine (52 hours with artemether v 61 hours
with quinine; WMD –8.6 hours, 95% CI –22.5 hours to + 5.3 hours). The second subsequent RCT
(41 children with severe malaria in Sudan, 40 analysed) compared intramuscular artemether
(3.2 mg/kg loading dose, then 1.6 mg/kg daily) versus intravenous quinine (loading dose 20 mg/kg,
then 10 mg/kg 8 hourly). [11]  It found that artemether significantly increased fever clearance time
but found no significant difference between artemether and quinine in time to parasite clearance
(mean fever clearance time: 30.5 hours with artemether v 18 hours with quinine, P = 0.02; mean
parasite clearance time: 16 hours with artemether v 22.4 hours with quinine, P > 0.05). It found
that one child died with quinine compared with no deaths with artemether (0/20 [0%] with artemether
v 1/21 [5%] with quinine; P value not reported). The third subsequent RCT (77 comatose children,
aged 3 months to 15 years, with cerebral malaria) compared intramuscular artemether versus in-
travenous quinine. [12]  It found no significant difference in death rates between artemether and
quinine (3/38 [8%] with artemether v 2/39 [5%]; P value not reported). There was no significant
difference in mean fever clearance time, coma recovery time, and parasite clearance time (fever
clearance time: 31 hours with artemether v 36 hours with quinine; coma recovery time: 21 hours
with artemether v 26 hours with quinine; parasite clearance time: 36 hours with artemether v 41
hours with quinine; P value not reported for any comparison). The fourth subsequent RCT (46
children, age up to 14 years, with severe malaria in India) compared intramuscular artemether
versus intravenous quinine. [13]  It found no significant difference in mortality (5/23 with artemether
v 6/23 with quinine; OR 0.79, 95% CI 0.2 to 3.06). It found that artemether significantly improved
parasite clearance time and coma recovery time compared with quinine, but found no significant
difference in fever clearance time (parasite clearance time: 40.9 hours with artemether v 51.9 hours
with quinine, WMD –11.0 hours, 95% CI –14.47 hours to –7.53 hours; coma recovery time: 34.8
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hours with artemether v 40.8 hours with quinine, WMD –6.0 hours, 95% CI –10.41 hours to –1.59
hours; fever clearance time: 44.5 hours with artemether v 45.9 hours with quinine, WMD –1.4 hours,
95% CI –5.71 hours to + 2.91 hours). The fifth subsequent RCT (37 children with cerebral malaria
in Nigeria) compared intramuscular artemether (3.2 mg/kg stat, then 1.6 mg/kg every 12 hours for
3 days) versus intravenous quinine (10 mg/kg every 8 hours). [14]  It found that artemether signifi-
cantly reduced fever clearance time and coma recovery time compared with quinine, but found
that quinine significantly increased parasite clearance on day 7 compared with artemether (fever
clearance time: 34.7 hours with artemether v 53.2 hours with quinine, P < 0.01; coma recovery
time: 12.5 hours with artemether v 17.4 hours with quinine, P < 0.05; parasite clearance on day 7:
15/18 [83.8%] with artemether v 19/19 [100%] with quinine, P < 0.05). There was no significant
difference in mortality between treatment groups (AR 1/18 [5.5%] with artemether v 2/19 [10.5%]
with quinine; P value not significant).
Harms: The second review stated that not all studies reported on harms. [9]  Among those that did, the
proportion affected was small and similar between groups. The harms reported included nausea,
vomiting, diarrhoea, abdominal pain, pruritus, urticaria, rash and injection site pain, and abscess.
The second subsequent RCT found that one child treated with quinine developed hypoglycaemia
(0/20 [0%] with artemether v 1/21 [5%] with quinine; P value not reported). [11]  It reported no neu-
rological problems in either treatment group after 28 days of follow up. The third subsequent RCT
found no significant difference in transient neurological sequelae between artemether and quinine
(2/38 [5%] with artemether v 1/39 [3%] with quinine; P value not reported). [12] The fourth subsequent
RCT reported no important adverse effects with either artemether or quinine, and provided no details.
[13] The fifth subsequent RCT found no significant difference in neurological sequelae between
treatment groups (AR 2/18 [11.1%] with artemether v 2/19 [10.5%]; P > 0.10). [14]
Comment: The third subsequent RCT did not use loading doses of either artemether or quinine at the beginning
of treatment. [12] Treatment allocation in the fourth subsequent RCT was quasi-randomised by
date of admission. [13] We found a sixth subsequent RCT (52 people). [15]  However, it was not
clear whether participants had severe malaria, and outcomes were poorly reported.
OPTION INTRAVENOUS ARTESUNATE VERSUS QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Intravenous artesunate compared with intravenous quinine Intravenous artesunate may reduce mortality compared
with intravenous quinine ( low-quality evidence ).
Fever clearance time
Intravenous artesunate compared with intravenous quinine Intravenous artesunate may reduce the time to clearance
of fever compared with intravenous quinine ( low-quality evidence ).
Coma recovery time
Intravenous artesunate compared with intravenous quinine Intravenous artesunate may be as effective as intravenous
quinine at reducing the time taken to recover from coma ( low-quality evidence ).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found no systematic reviews. We found five RCTs. [16] [17] [18] [19] [20] The first RCT (113
adults with severe malaria in Thailand) compared intravenous artesunate (2.4 mg/kg initially,
1.2 mg/kg 12 hours later, then 1.2 mg/kg daily) versus intravenous quinine (20 mg/kg initially, then
10 mg/kg 8 hourly). [16]  It found no significant difference between treatments in mortality after 300
hours (7/59 [12%] artesunate v 12/54 [22%] quinine; RR 0.53, 95% CI 0.23 to 1.26). It found that
artesunate significantly improved parasite clearance time , but found no significant difference in
fever clearance time  or coma recovery time  (parasite clearance time: 63 hours with artesunate
v 76 hours with quinine, P = 0.019; fever clearance time: 41 hours with artesunate v 65 hours with
quinine, P = 0.2; coma recovery time: 17 hours with artesunate v 18 hours with quinine, P = 0.6).
The second RCT (80 children with complicated malaria in India) compared intravenous artesunate
(2.4 mg/kg iv stat, followed by 1.2 mg/kg after 6 hours, then once daily for 5 days) versus intravenous
quinine (20 mg/kg loading dose, followed by 10 mg/kg iv 8 hourly). [17]  It found that artesunate
significantly reduced parasite clearance time, fever clearance time, and coma recovery time com-
pared with quinine, with no significant difference in mortality between treatment groups (parasite
clearance time: 52.2 hours with quinine v 41.7 with artesunate, P < 0.05; fever clearance time: 62.2
hours with quinine v 43.6 hours with artesunate, P < 0.05; coma recovery time: 70.2 hours with
quinine v 50.4 hours with artesunate, P < 0.05; mortality: 8/40 [20%] with quinine v 5/40 [12.5%]
with artesunate, P > 0.05; see comment below). [17] The third small RCT (35 adults with severe
malaria in India) compared intravenous artesunate (2.4 mg/kg iv stat, followed by 1.2 mg/kg iv or
2 mg/kg orally for 6 days) versus intravenous quinine (20 mg/kg loading dose, then 10 mg/kg 8
hourly). [18]  It found no significant difference between treatments in mortality (mortality: 1/17 [5.9%]
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with artesunate v 1/18 [5.6%] with quinine; P = 0.96). It found that artesunate significantly reduced
the median fever clearance time compared with quinine (median fever clearance time: 32 hours
with artesunate v 58 hours with quinine; P = 0.023). The intraquartile range for the time taken to
clear 50% and 90% of the parasites suggested the fever clearance time with artesunate was
shorter (for 50% clearance: quinine intraquartile range 14 to 24 hours, v artesunate intraquartile
range 8 to 16 hours; P = 0.01). [18] The fourth large RCT (1259 adults and 202 children with severe
malaria in Bangladesh, India, Indonesia, and Myanmar) compared intravenous artesunate (2.4 mg/kg
iv stat, then at 12 hours and 24 hours, then daily) versus intravenous quinine (20 mg/kg loading
dose, then 10 mg/kg three times daily). [19]  It found that mortality was significantly lower with arte-
sunate compared with quinine (mortality, intention to treat analysis: 107/730 [15%] with artesunate
v 164/731 [22%] with quinine; P = 0.0002, RR 0.69, 95% CI 0.54 to 0.83). [19] The fifth RCT (61
adults with cerebral malaria in Vietnam) compared intravenous artesunate (60 mg at 0 hours and
4 hours, then 60 mg at 24 hours and 48 hours) versus intravenous quinine (500 mg 8 hourly). [20]
It found no significant difference in mortality between the treatments (5/31 [16.5%] with artesunate
v 8/30 [26.7%] with quinine; P value not stated).It reported that the parasite and fever clearance
times were significantly faster with artesunate compared with quinine (parasite clearance time:
28.1 hours with artesunate v 51.2 hours with quinine, P value not stated; fever clearance time: 39
hours with artesunate v 78 hours with quinine, P value not stated). The mean coma recovery time
was not significantly different between the groups (coma recovery time: 68.9 hours with artesunate
v 58.1 hours with quinine; P value not stated).
Harms: The first RCT found that artesunate significantly reduced hypoglycaemia compared with quinine
(6/59 [10%] with artesunate v 15/54 [28%] with quinine; RR 0.37, 95% CI 0.15 to 0.88). [16]  It found
that one person treated with artesunate developed an urticarial rash. The second RCT found no
adverse events with artesunate, but found that people in the quinine group experienced nausea
(20/40 [50%]), headache (16/40 [40%]), vomiting (12/40 [30%]), tinnitus (8/40 [20%]), vertigo (4/40
[10%]), circulatory failure (2/50 [4%]), and sudden blindness (1/40 [3%]) at 28 days. [17] The third
RCT reported no significant adverse events. [18] The fourth RCT found the risk of hypoglycaemia
was significantly higher with quinine compared with artesunate (19/731 [3%] with quinine v 6/730
[< 1%] with artesunate; P = 0.009, RR 3.2, 95% CI 1.3 to 7.8). There was no significant difference
in the neurological sequelae between the two groups (7/730 [1%] with artesunate v 3/731[<1%]
with quinine; P = 0.23). [19] The fifth RCT reported no significant adverse events in patients receiving
artesunate. [20] It did not report on adverse effects with quinine.
Comment: Treatment allocation in the second RCT was quasi-randomised by odd and even numbers. [17]
The first two RCTs and third and fifth RCTs may have been underpowered to detect a clinically
important difference. [16] [17] [18] [20] . The fourth RCT was a large multicentre trial which showed
a significant reduction in mortality with artesunate compared with quinine. [19] The intention to treat
analysis included patients with unconfirmed malaria. In total, 79/1461 (5%) participants included
had blood-smear negative malaria. [19]  In the third RCT, all participants received at least 24 hours
of intravenous therapy and completed a 7 day course of treatment. [18]  Fixed doses of artesunate
and quinine were used in the fifth RCT in contrast to the other RCTs which calculated doses based
on bodyweight.
OPTION QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with intramuscular artemether Intravenous or intramuscular quinine seems to be as effective as intramus-
cular artemether at reducing mortality in people with severe malaria ( moderate-quality evidence ).
Compared with intravenous artesunate Intravenous quinine may be less effective at reducing mortality compared
with intravenous artesunate ( low-quality evidence ).
Compared with rectal artemisinin derivatives Quinine seems to be as effective as rectal artemether, artemisinin,
artesunate, and dihydroartemisinin at reducing mortality in people with severe malaria ( high-quality evidence ).
Compared with intramuscular arteether Quinine seems to be as effective as intramuscular arteether at reducing
mortality after 28 days in children with severe malaria (moderate-quality evidence).
Fever clearance
Compared with intramuscular artemether Intravenous or intramuscular quinine seems to be as effective as intramus-
cular artemether at eradicating fever in people with severe malaria (moderate-quality evidence).
Compared with intravenous artesunate Intravenous quinine may be less effective than intravenous artesunate at
reducing the time to clearance of fever (low-quality evidence).
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Compared with rectal artemisinin derivatives Quinine seems to be as effective as rectal artemether, artemisinin,
artesunate, and dihydroartemisinin at reducing time to eradication of fever in people with severe malaria (moderate-
quality evidence).
Compared with intramuscular arteether Quinine seems to be as effective as intramuscular arteether at reducing time
to clearance of fever in children with severe malaria (moderate-quality evidence).
Recovery from coma
Compared with intramuscular artemether  Intravenous or intramuscular quinine seems to be as effective as intramus-
cular artemether at reducing time spent in a coma in people with severe malaria (moderate-quality evidence).
Compared with intravenous artesunate Intravenous quinine may be as effective as intravenous artesunate at reducing
the time taken to recover from coma (low-quality evidence).
Compared with rectal artemisinin derivatives Quinine seems to be as effective as rectal artemether and artemisinin
at reducing time to recovery of coma in people with severe malaria (high-quality evidence).
Compared with intramuscular arteether Quinine seems to be as effective as intramuscular arteether at reducing time
to recovery from coma in children with severe malaria (moderate-quality evidence).
Neurological sequelae
Compared with intramuscular artemether Intravenous or intramuscular quinine seems to be as effective as intramus-
cular artemether at preventing neurological sequelae in people with severe malaria (high-quality evidence).
Note
We found no direct information about whether quinine is better than no active treatment in people with severe
malaria.
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: Quinine versus placebo:
We found no systematic reviews or RCTs comparing quinine with placebo in people with severe,
life-threatening malaria. Placebo or no treatment controlled trials of antimalarial treatment in people
with severe malaria would be considered unethical.
Quinine versus intramuscular artemether:
See benefits of intramuscular artemether, p 3 .
Quinine versus intravenous artesunate:
See benefits of intravenous artesunate, p 4 .
Quinine versus intramuscular arteether:
See benefits of intramuscular arteether, p 9 .
Quinine versus rectal artemisinin derivatives:
See benefits of rectal artemisinin derivatives, p 8 .
Harms: We found no systematic reviews or RCTs comparing quinine with placebo in people with severe,
life-threatening malaria.
Quinine versus intramuscular artemether:
See harms of intramuscular artemether, p 4 .
Quinine versus intravenous artesunate:
See harms of intravenous artesunate, p 5 .
Quinine versus intramuscular arteether:
See harms of intramuscular arteether, p 10 .
Quinine versus rectal artemisinin derivatives:
See harms of artemisinin derivatives, p 9 .
Comment: Clinical guide:
International consensus has historically recommended quinine for the treatment of severe falciparum
malaria. Controlled trials will generally compare new treatments against this standard.
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OPTION HIGH INITIAL DOSE QUININE COMPARED WITH STANDARD REGIMES. . . . . . . . . . . . . . . . .
Mortality
High initial dose compared with standard regimens Giving a high initial dose of quinine does not seem to reduce
mortality compared with standard regimens ( moderate-quality evidence ).
Fever clearance time
High initial dose compared with standard regimens Giving a high initial dose of quinine reduces the time to clearance
of fever compared with standard regimens (moderate-quality evidence).
Coma recovery time
High initial dose compared with standard regimens Giving a high initial dose of quinine does not seem to reduce the
time to recovery from coma compared with standard regimens (moderate-quality evidence).
Adverse effects
High initial dose compared with standard regimens Initial high-dose quinine regimens do not seem to increase the
risk of neurological sequelae compared with standard regimens (moderate-quality evidence). High-initial-dose quinine
may increase transient partial hearing loss compared with no loading dose.
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found one systematic review (search date 2004, 4 RCTs, 144 people). [21] The systematic review
found no significant difference in mortality between high initial dose of quinine (20 mg salt/kg or
16 mg base/kg given im or iv) and no loading dose, followed in both groups by standard dose quinine
(3 RCTs; 4/70 [5.7%] died with high initial dose v 7/74 [9.5%] with no loading dose; RR 0.62, 95%
CI 0.19 to 2.04). Two RCTs (99 children) found no significant difference between high initial dose
and no loading dose in mean time to recover consciousness (WMD + 5.17 hours, 95% CI –1.14
hours to + 11.47 hours). Parasite clearance time and fever clearance time  were shorter for the
high initial dose quinine group than for the group with no loading dose (parasite clearance time: 2
RCTs, 67 people, WMD –7.4 hours, 95% CI –13.2 hours to –1.6 hours; fever clearance time: 2
RCTs, 68 people, WMD –11.1 hours, 95% CI –20.0 hours to –2.2 hours).
Harms: The systematic review found no significant difference between high initial dose of quinine and no
loading dose in the rate of hypoglycaemia (2 RCTs; 4/35 [11%] had hypoglycaemia with high initial
dose v 3/37 [8%] with no loading dose; RR 1.39, 95% CI 0.32 to 6.00). [21]  One RCT (33 people)
included in the review found that high initial dose quinine significantly increased transient partial
hearing loss compared with no loading dose (10/17 [59%] with high initial dose v 3/16 [19%] with
no loading dose; RR 3.14, 95% CI 1.05 to 9.38). [22]  Another RCT (three arm RCT; 59 children)
included in the review found no significant difference between high initial dose of quinine and no
loading dose in neurological sequelae (1/18 [6%] with high initial dose v 2/21 [10%] with no loading
dose; RR 0.58, 95% CI 0.06 to 5.91). [23]
Comment: The RCTs may have been too small to detect a clinically important difference. [23] [22] [24] [25]
Clinical guide:
International consensus has historically recommended quinine for the treatment of severe falciparum
malaria. Controlled trials will generally compare new treatments against this standard.
OPTION INTRAMUSCULAR VERSUS INTRAVENOUS QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Intramuscular quinine compared with intravenous quinine Mortality rates are similar with high-dose intramuscular
quinine compared with high-dose intravenous quinine ( moderate-quality evidence ).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found no systematic review but found one RCT. [23] The RCT (59 Kenyan children < 12 years
old in 1989–1990) compared high loading dose intramuscular quinine (20 mg salt/kg initially followed
by 10 mg salt/kg 12 hourly) versus high loading dose intravenous quinine (20 mg salt/kg initially
followed by 10 mg salt/kg 12 hourly) versus standard dose intravenous quinine (10 mg salt/kg 12
hourly) in severe falciparum malaria. [23]  It found no significant difference in mortality, mean parasite
clearance time , or recovery time to drinking or walking between high dose intramuscular and high
dose intravenous quinine, but lacked power to detect a clinically important difference (mortality:
3/20 [15%] deaths with im quinine v 1/18 [5.6%] with iv quinine, RR 2.7, 95% CI 0.3 to 23.7; mean
parasite clearance time: 57 hours with im quinine v 58 hours with iv quinine, WMD –1.0 hours, 95%
CI –12.2 hours to + 10.2 hours; mean recovery times to drinking: 47 hours with im quinine v 32
hours with iv quinine, WMD + 15 hours, 95% CI –5.6 hours to + 35.6 hours; mean recovery times
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to walking: 98 hours with im quinine v 96 hours with iv quinine, WMD + 2.0 hours, 95% CI –24.5
hours to + 28.5 hours).
Harms: In the RCT, neurological sequelae were reported in two children in the intramuscular group, and
one child in the intravenous group had transient neurological sequelae that were not specified (2/20
[10%] with im quinine v 1/18 [5.6%] with iv quinine; RR 1.8, 95% CI 0.2 to 18.2). [23]
Comment: Quinine concentration profiles were similar with both routes of administration, and peak concentra-
tions were achieved soon after intramuscular injection.The sample size might have been insufficient
to rule out clinically important differences. [23]
Clinical guide:
International consensus has historically recommended quinine for the treatment of severe falciparum
malaria. Controlled trials will generally compare new treatments against this standard.
OPTION RECTAL ARTEMISININ DERIVATIVES (ARTEMETHER, ARTEMISININ, ARTESUNATE, OR
DIHYDROARTEMISININ) VERSUS QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with quinine Rectal artemether, artemisinin, artesunate, and dihydroartemisinin seem to be as effective
as quinine at reducing mortality in people with severe malaria ( high-quality evidence ).
Fever clearance time
Compared with quinine Rectal artemether, artemisinin, artesunate, and dihydroartemisinin seem to be as effective
as quinine at reducing time to eradication of fever in people with severe malaria ( moderate-quality evidence ).
Coma recovery time
Compared with quinine Rectal artemether and artemisinin seem to be as effective as quinine at reducing time to re-
covery of coma in people with severe malaria (high-quality evidence).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: Rectal artemether versus quinine:
We found one RCT conducted in Uganda comparing rectal artemether (children weighing up to
 8.9 kg given 40 mg daily; children 9–18.9 kg given 80 mg dose immediately, then 40 mg daily;
children 19–27.9 kg given 120 mg dose immediately, then 80 mg daily) versus intravenous quinine
(20 mg/kg dose immediately, then 10 mg/kg 8 hourly) over 7 days. [26] The RCT found no significant
difference in mortality between rectal artemether and intravenous quinine treatment (103 children
with cerebral malaria, aged 6 months to 5 years; mortality: 6/51 [12%] with artemether v 10/52
[19%] with quinine; RR 0.78, 95% CI 0.50 to 1.19). It found no significant difference in the parasite
and fever clearance times  (mean parasite clearance time : 54.2 hours with artemether v 55.0
hours with quinine, P = 0.48; mean fever clearance time: 33.2 hours with artemether v 24.1 hours
with quinine, P = 0.08).There was no significant difference in the time taken to regain consciousness
(mean time: 30.1 hours with artemether v 22.7 hours with quinine; P = 0.1).
Rectal artemisinin versus quinine:
We found one systematic review (search date 1999, 3 RCTs) comparing rectal artemisinin versus
quinine in severe malaria. [9] Two RCTs were conducted in Vietnam and one in Ethiopia
(1996–1997). Meta-analysis found lower mortality with artemisinin and quicker coma recovery
time , but the differences were not significant (mortality: 3 RCTs, 9/87 [10%] with artemisinin v
16/98 [16%] with quinine, RR 0.73, 95% CI 0.35 to 1.50; coma recovery time: 2 RCTs, 59 people,
WMD –9.0 hours, 95% CI –19.7 hours to + 1.7 hours). Fever clearance time was not significantly
different (no figures provided).
Rectal artesunate versus quinine:
We found one RCT (144 people with moderately severe malaria: 109 children in Malawi and 35
adults in South Africa) comparing rectal artesunate (single dose 10 mg/kg) and intravenous quinine
(10 mg/kg at 0, 4, and 10 hours, then every 12 hours until oral treatment was tolerated). [27]  It found
no deaths in either treatment group. In children, artesunate significantly reduced fever clearance
time and parasite clearance time compared with quinine (median fever clearance time: 20 hours
with artesunate v 44 hours with quinine, P < 0.0001; mean parasite clearance time: 36 hours with
artesunate v 45 hours with quinine, P = 0.0003). It found no significant difference in the proportion
of children able to drink at 24 hours (AR 77/87 [89%] with artesunate v 21/22 [95%] with quinine;
P = 0.3). In adults, there was no significant difference in fever clearance time and parasite clearance
time (mean parasite clearance time: 49 hours with artesunate v 63 hours with quinine, P = 0.10;
median fever clearance time: 36 hours with artesunate v 23 hours with quinine, P = 0.116).
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Rectal dihydroartemisin versus quinine:
We found one RCT (67 people aged 2–60 years with severe malaria in Kenya in 1998), which
compared rectal dihydroartemisin (160 mg initially, then 80 mg for 2 days for people > 16 years;
variable dosage depending on age in people < 16 years) versus intravenous quinine (20 mg/kg
initially, then 10 mg/kg 8 hourly). [28]  It found no deaths with either treatment. It found that dihy-
droartemisinin significantly improved parasite clearance time compared with quinine, but found no
significant difference in fever clearance time (mean parasite clearance time: 38 hours with dihy-
droartemisinin v 49 hours with quinine, P = 0.04; mean fever clearance time: 27.9 hours with dihy-
droartemisinin v 22.0 hours with quinine, P = 0.25).
Harms: Rectal artemether versus quinine:
The RCT found no significant difference in the number of children vomiting (2/51 with artemether
v 5/52 with quinine; P = 0.235). [26]
Rectal artemisinin versus quinine:
One RCT found that artemisinin significantly reduced the risk of hypoglycaemia compared with
quinine (3/30 [10%] with artemisinin v 19/30 [63%] with quinine; RR 0.16, 95% CI 0.05 to 0.48). [29]
Rectal artesunate versus quinine:
The RCT found no significant difference in adverse events between treatment groups (data not
reported) at 28 days, but found local reactions at quinine injection sites in three adults. [27]  No ad-
verse neurological events were reported with artesunate, and 1/8 (12.5%) adults treated with quinine
developed transient dysdiadochokinesis.
Rectal dihydroartemisin versus quinine:
The RCT found that dihydroartemisin significantly reduced tinnitus compared with quinine (1/30
[3%] with dihydroartemisinin v 10/37 [27%] with quinine; OR 0.09, 95% CI 0.01 to 0.78). [28]
Comment: Rectal artesunate versus quinine:
In the RCT, the sample size of the adult group may have been too small to detect a clinically impor-
tant difference. [27]
Clinical guide:
A single dose of rectal artesunate does not cure malaria and must be followed by a full course of
known effective treatment.
OPTION INTRAMUSCULAR ARTEETHER VERSUS QUININE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with quinine Intramuscular arteether seems to be as effective as quinine at reducing mortality after 28
days in children with severe malaria ( moderate-quality evidence ).
Fever clearance time
Compared with quinine Intramuscular arteether seems to be as effective as quinine at reducing time to clearance of
fever in children with severe malaria (moderate-quality evidence).
Coma recovery time
Compared with quinine Intramuscular arteether seems to be as effective as quinine at reducing time to recovery
from coma in children with severe malaria (moderate-quality evidence).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found one systematic review (search date 2004, 2 RCTs, 194 children) comparing arteether
versus quinine in children with cerebral malaria. [30]  It found no significant difference in mortality,
time to regain consciousness, parasite clearance time , fever clearance time , and parasite
clearance on days 7 and 28 between treatment groups (mortality: 2 RCTs, 194 people, AR 18/99
[18%] with arteether v 23/95 [24%] with quinine, RR 0.75, 95% CI 0.43 to 1.30; time to regain
consciousness: 2 RCTs, 153 people, 81 hours with arteether v 72 hours with quinine, WMD + 6.69
hours, 95% CI –3.19 hours to + 16.57 hours; parasite clearance time: 2 RCTs, 153 people, 81
hours with arteether v 71 hours with quinine, WMD + 1.32 hours, 95% CI –6.48 hours to + 9.11
hours; fever clearance time: 2 RCTs, 146 people, 75 hours with arteether v 71 hours with quinine,
WMD + 5.10 hours, 95% CI –5.76 hours to + 15.95 hours; presence of parasites at day 7: 2 RCTs,
151 people, AR 5/79 [6%] with arteether v 8/72 [11%] with quinine, RR 0.57, 95% CI 0.19 to 1.67;
presence of parasites at day 28: 1 RCT, 78 people, AR 11/41 [27%] with arteether v 13/37 [35%]
with quinine, RR 0.76, 95% CI 0.39 to 1.49).
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Harms: One RCT identified by the review found no significant difference in adverse events or residual
neurological complications between treatment groups at 28 days (adverse events: 36/48 [75%]
with arteether v 34/44 [77%] with quinine, RR 0.97, 95% CI 0.77 to 1.22; residual neurological
complications: 5/34 [14.7%] with arteether v 3/24 [12.5%] with quinine, RR 1.18, 95% CI 0.31 to
4.46). [31]
Comment: The RCTs included in the review were small and the review reported that it lacked power to detect
clinically important differences. [30]
QUESTION What are the effects of adjunctive treatment for complicated falciparum malaria in non-
pregnant people?
OPTION EXCHANGE BLOOD TRANSFUSION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with no exchange blood transfusion Exchange blood transfusion may not reduce mortality rates compared
with no exchange transfusion in people with severe malaria taking antimalarial drugs ( very low-quality evidence ).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found one systematic review (search date 2001). [32]  It found no suitable RCTs in people with
malaria. We found no additional RCTs that met our inclusion criteria (see comment below).
Harms: We found no RCTs.
Comment: We found one systematic review of case control studies [32]  and one small RCT. [33] The review
(search date 2001, 8 studies, 279 people) found no significant difference in mortality between ex-
change transfusion plus antimalarial drugs and antimalarial drugs only (8 studies; OR for death
1.2, 95% CI 0.7 to 2.1). [32]  Admission criteria for exchange transfusion varied in the included
studies, but generally, parasitaemia was greater than 10%, and most people had failed to improve
after 24 hours of antimalarial treatment. The methods and volumes used for exchange transfusion
also varied. Those who received exchange blood transfusions had higher mean levels of para-
sitaemia before treatment began (26% with exchange transfusion v 11% with no exchange trans-
fusion; P < 0.05) and fulfilled more World Health Organization criteria for the diagnosis of severe
malaria (mean 3.6 with exchange transfusion v 2.8 with no exchange transfusion; P = 0.03). The
RCT compared exchange transfusion plus antimalarial drugs versus antimalarial drugs alone, but
it included only eight people. [33]
OPTION INITIAL BLOOD TRANSFUSION FOR TREATING MALARIAL ANAEMIA. . . . . . . . . . . . . . . . .
Mortality
Compared with no transfusion Initial blood transfusion may not reduce mortality in clinically stable children with severe
malaria compared with conservative treatment or iron supplements ( very low-quality evidence ).
Adverse effects
Adverse effects may be more common overall with initial blood transfusion, although the risk of severe adverse effects
may not be increased.
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found one systematic review (search date 2005, 2 RCTs, 230 children with malarial anaemia;
packed cell volume range 12–17%). [34] The first RCT (116 children) compared initial blood trans-
fusion versus conservative treatment in children from Tanzania, and the second RCT (114 children)
compared blood transfusion versus iron supplements in children from the Gambia. Both trials ex-
cluded children who were clinically unstable with respiratory distress or signs of cardiac failure.
Meta-analysis found fewer deaths in the transfused children, but the difference was not significant
(1/118 [1%] with transfusion v 3/112 [3%] with control; RR 0.41, 95% CI 0.06 to 2.70). We found
no RCTs examining the effects of transfusion in adults with malaria.
Harms: Coma and convulsions occurred significantly more often after transfusion (8/118 [6.8%] with
transfusion v 0/112 [0%] without transfusion; RR 8.6, 95% CI 1.1 to 66.4). [34]  Seven of the eight
adverse events occurred in one RCT. Meta-analysis combining deaths and severe adverse events
found no significant difference between people who received transfusions and people who did not
(8/118 [7%] with transfusion v 3/112 [3%] without transfusion; RR 2.5, 95% CI 0.7 to 9.3). Trans-
mission of hepatitis B or HIV was not reported.
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Comment: Studies were small and loss to follow up was greater than 10%, both of which are potential sources
of bias. [34]  In the first RCT, one child in the transfusion group and one child in the conservative
treatment group required an additional transfusion after clinical assessment. In the second RCT,
10 children allocated to receive iron supplements later required transfusion when packed cell volume
fell below 12% or they showed signs of respiratory distress.
Clinical guide:
Transfusion may be clinically essential in some circumstances.
OPTION ANTICONVULSANTS (PHENOBARBITONE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with no anticonvulsants Phenobarbitone, especially at higher doses, may increase mortality compared
with no anticonvulsants in people with cerebral malaria ( low-quality evidence ).
Convulsions
Compared with no anticonvulsants Phenobarbitone reduces the risk of convulsions in people with cerebral malaria
over 4 weeks ( moderate-quality evidence ).
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: We found one systematic review comparing anticonvulsants versus control (placebo or no anticon-
vulsants) for treating cerebral malaria. [35]  It examined the routine use of anticonvulsants for treating
people with cerebral malaria. The review identified three RCTs, all of which assessed phenobarbi-
tone. The review found that phenobarbitone significantly reduced convulsions within 4 weeks of
attending hospital compared with control (search date 2004, 3 RCTs, 573 participants; convulsions:
24/296 [8%] with phenobarbitone v 78/277 [28%] with control; RR 0.27, 95% CI 0.14 to 0.52).
Overall, the review found no significant difference in mortality between phenobarbitone and control
(AR of death: 67/296 [23%] with phenobarbitone v 52/277 [19%] with control; RR 1.30, 95% CI
0.58 to 2.88). However, meta-analysis of only the two trials with adequate allocation concealment
found a significant increase in mortality with phenobarbitone (2 RCTs, 388 participants; AR of
death: 38/194 [20%] with phenobarbitone v 19/194 [10%] with control; RR 1.98, 95% CI 1.19 to
3.28).
Harms: The review found limited evidence that phenobarbitone can increase mortality (see benefits section
above).
Comment: The RCTs included in the review used different doses of phenobarbitone (3.5 mg/kg, 10 mg/kg,
and 20 mg/kg). [35] The highest dose of phenobarbitone (20 mg/kg) significantly increased mortal-
ity compared with placebo (AR: 30/170 [18%] with phenobarbitone v 14/170 [8%] with placebo; RR
2.14, 95% CI 1.18 to 3.90).
OPTION DEXAMETHASONE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
Compared with placebo Dexamethasone does not reduce mortality compared with placebo ( moderate-quality evidence
).
Coma recovery time
Compared with placebo The effects of dexamethasone on time to recover from coma are unclear compared with
placebo ( low-quality evidence ).
Adverse effects
Dexamethasone has been associated with increased risks of gastrointestinal bleeding and seizures.
For GRADE evaluation of interventions for severe, life-threatening malaria, see table, p 14 .
Benefits: Dexamethasone versus placebo:
We found one systematic review (search date 2004, 2 RCTs, 143 people with severe/cerebral
malaria treated with quinine), which compared dexamethasone versus placebo over 48 hours. [36]
One RCT was conducted in Indonesia and the other in Thailand. The review found no significant
difference in mortality (14/71 [20%] with dexamethasone v 16/72 [23%] with placebo; RR 0.89,
95% CI 0.48 to 1.68). One RCT found a longer mean time between start of treatment and coma
recovery with dexamethasone (76 hours with dexamethasone v 57 hours with placebo; P < 0.02),
[37]
 but the other RCT found no significant difference (83.4 hours with dexamethasone v 80.0 hours
with placebo; WMD + 3.4 hours, 95% CI –31.3 hours to + 38.1 hours). [38]
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Harms: The review found that dexamethasone significantly increased gastrointestinal bleeding and seizures
compared with placebo (gastrointestinal bleeding: 7/71 [10%] with dexamethasone v 0/72 [0%]
with placebo, RR 8.17, 95% CI 1.05 to 63.6; seizures: 11/71 [15.5%] with dexamethasone v 3/72
[4%] with placebo, RR 3.32, 95% CI 1.05 to 10.47). [36]
Comment: No effect of steroids on mortality was shown, but the trials were small. The effect of steroids on
disability was not reported.
GLOSSARY
Coma recovery time The time between commencing treatment and regaining consciousness.
Fever clearance time The time between commencing treatment and the temperature returning to normal.
Parasite clearance time (PCT) The time between commencing treatment and the first negative blood test. PCT 50
is the time taken for parasites to be reduced to 50% of the first test value, and PCT 90 is the time taken for parasites
to be reduced to 10% of the first test value.
High-quality evidence Further research is very unlikely to change our confidence in the estimate of effect
Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate
of effect and is likely to change the estimate
Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate
of effect and may change the estimate
Very low-quality evidence Any estimate of effect is very uncertain
SUBSTANTIVE CHANGES
Intravenous artesunate versus quinine Three RCTs added. [18] [19] [20]  benefits and harms data enhanced; re-
categorised from Unknown effectiveness to Likely to be beneficial.
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TABLE GRADE evaluation of interventions for severe, life-threatening malaria
Mortality, fever clearance, coma recovery time, neurological sequelae, adverse effectsImportant out-
comes
CommentGRADEEf-
fect
size
Di-
rect-
ness
Con-
sis-
ten-
cy
Qual-
ity
Type
of
evi-
dence
ComparisonOutcomeNumber of
studies (partic-
ipants)
What are the effects of antimalarial treatments for complicated falciparum malaria in non-pregnant people?
Consistency point deduct-
ed for conflicting results
from different analyses
Modeer-
ate
00–104Intramuscular
artemether v quinine
(intramuscular or intra-
venous)
MortalityAt least 16 (at
least 2448) [8][9] [10] [11]
[12] [13] [14]
Consistency point deduct-
ed for conflicting results
Moder-
ate
00–104Intramuscular
artemether v quinine
(intramuscular or intra-
venous)
Fever recov-
ery time
12 (2225) [8][10] [11] [12]
[13] [14]
Consistency point deduct-
ed for conflicting results
Modeer-
ate
00–104Intramuscular
artemether v quinine
(intramuscular or intra-
venous)
Coma recov-
ery time
12 (2225) [8][10] [11] [12]
[13] [14]
High00004Intramuscular
artemether v quinine
Neurological
sequelae
At least 12 (at
least 2247) [8][9] [10] (intramuscular or intra-
venous)
Consistency point deduct-
ed for conflicting results.
Low0–1–104Intravenous artesunate
v intravenous quinine
Mortality5 (1548) [16][17] [18] [19]
[20] Directness point deducted
for uncertain diagnosis in
some studies
Quality point deducted for
randomisation flaws. Con-
Low00–1–14Intravenous artesunate
v intravenous quinine
Fever clear-
ance time
4 (289) [16][17] [18] [20]
sistency point deducted
for conflicting results.
Quality point deducted for
methodological flaws.
Low0–1–104Intravenous artesunate
v intravenous quinine
Coma recov-
ery time
3 (254) [16][17] [20]
Consistency point deduct-
ed for conflicting results
High00004Intravenous quinine v
rectal artemisinin
derivatives
Mortality6 (499) [26][27] [28] [9]
Consistency point deduct-
ed for conflicting results
Moder-
ate
00–104Intravenous quinine v
rectal artemisinin
derivatives
Fever clear-
ance time
6 (499) [26][27] [28] [9]
High00004Intravenous quinine v
rectal artemisinin
derivatives
Coma recov-
ery time
4 (288) [26] [9]
Quality point deducted for
sparse data
Moder-
ate
000–14Quinine v intramuscular
arteether
Mortality2 (194) [30]
Quality point deducted for
sparse data
Moder-
ate
000–14Quinine v intramuscular
arteether
Fever clear-
ance time
2 (194) [30]
Quality point deducted for
sparse data
Moder-
ate
000–14Quinine v intramuscular
arteether
Coma recov-
ery time
2 (194) [30]
Quality point deducted for
sparse data
Mortality000–14Initial high-dose quinine
v standard dose
Mortality4 (144) [30]
Quality point deducted for
sparse data
Mortality000–14Initial high-dose quinine
v standard dose
Fever clear-
ance time
2 (68) [30]
Quality point deducted for
sparse data
Mortality000–14Initial high-dose quinine
v standard dose
Coma recov-
ery time
2 (99) [30]
Quality point deducted for
sparse data
Moder-
ate
000–14Initial high-dose quinine
v standard dose
Neurological
sequelae
1 (59) [30]
Quality point deducted for
sparse data
Moder-
ate
000–14Intravenous quinine v
intramuscular quinine
Mortality1 (59) [23]
What are the effects of adjunctive treatment for complicated falciparum malaria in non-pregnant people?
Quality point deducted for
baseline differences. Di-
Very low0–20–12Exchange blood trans-
fusion plus antimalarial
Mortality8 (279) [32]
rectness points deducteddrugs v antimalarial
drugs alone for inconsistent interven-
tions and inclusion criteria
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Mortality, fever clearance, coma recovery time, neurological sequelae, adverse effectsImportant out-
comes
CommentGRADEEf-
fect
size
Di-
rect-
ness
Con-
sis-
ten-
cy
Qual-
ity
Type
of
evi-
dence
ComparisonOutcomeNumber of
studies (partic-
ipants)
Quality point deducted for
poor follow-up. Directness
points deducted for exclu-
sion of seriously ill chil-
dren and for inconsistent
use of interventions
Very low0–20–14Initial blood transfusion
v no transfusion
Mortality2 (230) [34]
Quality point deducted for
allocation concealment
flaws. Consistency point
deducted for conflicting
results
Low00–1–14Anticonvulsants v
placebo or no anticon-
vulsants
Mortality3 (573) [35]
Quality point deducted for
allocation concealment
flaws
Moder-
ate
000–14Anticonvulsants v
placebo or no anticon-
vulsants
Convulsions3 (573) [35]
Quality point deducted for
sparse data
Moder-
ate
000–14Dexamethasone v
placebo
Mortality2 (143) [37][38]
Quality point deducted for
sparse data. Consistency
point deducted for conflict-
ing results
Low00–1–14Dexamethasone v
placebo
Coma recov-
ery time
2 (143) [37][38]
Type of evidence: 4 = RCT; 2 = Observational; 1 = Non-analytical/expert opinion. Consistency: similarity of results across studies
Directness: generalisability of population or outcomes
Effect size: based on relative risk or odds ratio
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